Pharmaceuticals group AstraZeneca saw product sales increase by 16% to $6.13bn in the third quarter of this year, its fifth consecutive quarter of growth. The group achieved new medicines sales growth of 62%, with its three therapy areas and all its sales regions producing “encouraging” performances. Sales were up by 46% in oncology,15% in respiratory therapies and 8% in cardiovascular, renal and metabolism treatments.
Revenues were also up by 35% in China, 31% in Japan, 25% in emerging markets, 17% in the US and 1% in Europe. Overall, in the first nine months of this year, sales were up by 13% to $17.3bn. Chief executive Pascal Soriot says Astrazeneca is “growing at pace” and has upgraded its sales guidance for the second consecutive quarter.